Search | Clinical Trials Finder

Conditions: ERα+ Breast Cancer, ESR1 Gene Mutation
Interventions: Tamoxifen, FES PET/CT; Drug · Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 19 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: CDB-2914, COB-2914; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leiomyoma
Interventions: CDB-2914; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 33 Years to 50 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Premenopause, Healthy
Interventions: Estradiol steroid infusion, Progesterone steroid infusion; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Menopause, Arteriosclerosis
Interventions: Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo; Drug
Lead sponsor: Kronos Longevity Research Institute; Other
Eligibility: 42 Years to 58 Years · Female only
Enrollment: 728 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: San Francisco, California • Jacksonville, Florida • Albany, New York + 3 more

Conditions: ER Positive, HER2 Positive Breast Cancer
Interventions: Elacestrant, Trastuzumab, Pertuzumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major, Menopause
Interventions: Estrogen; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Vulvovaginal Atrophy
Interventions: Vehicle, WC3011 Estradiol Vaginal Cream; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 48
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more

Conditions: Breast Cancer, Metastasis
Interventions: Dasatinib, Dasatinib 100 mg; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 7
States / cities: San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 4 more

Conditions: Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Bortezomib, Fulvestrant, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 21
States / cities: Farmington, Connecticut • New Haven, Connecticut • Weston, Florida + 8 more

Conditions: Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
Interventions: Diagnostic Laboratory Biomarker Analysis, Immunohistochemistry Staining Method, Medical Chart Review, Microarray Analysis, Study of Socioeconomic and Demographic Variables, Western Blotting; Other · Genetic
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Interventions: Datopotamab Deruxtecan; Drug
Lead sponsor: Nancy Lin, MD; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • Durham, North Carolina

Conditions: Postmenopause
Interventions: Premarin; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Overactive Bladder, Incontinence, Nocturia
Interventions: Estrogen Cream; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Sleep Initiation and Maintenance Disorders, Depression
Interventions: Estrogen Replacement Therapy, Zolpidem, placebo; Drug
Lead sponsor: Hadine Joffe, MD; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infertility, Diminished Ovarian Reserve, IVF
Interventions: Timing of injectable gonadotropins; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Genitourinary Syndrome of Menopause
Interventions: StrataMGT, Estrace 0.01% Vaginal Cream; Device · Drug
Lead sponsor: Stratpharma AG; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Laguna Hills, California • Miami, Florida • Johns Creek, Georgia

Conditions: Breast Cancer, Advanced Solid Tumor
Interventions: BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 6
States / cities: Birmingham, Alabama • New Haven, Connecticut • St Louis, Missouri + 3 more

Conditions: Arginine Vasopressin Deficiency, Oxytocin Deficiency, Pediatric Disease, Hypopituitarism
Interventions: Norethindrone Acetate-Ethinyl Estradiol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 7 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypopituitarism
Interventions: Human Growth Hormone (1-134), Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Metabolic Syndrome
Interventions: Zoladex, Testosterone gel, Anastrozole Pill, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anorexia Nervosa, Osteoporosis
Interventions: estradiol 0.045 mg/levonorgestrel 0.015mg; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Search by objective public record fields.

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

Effect of Race on Gonadotropin Responses

Kronos Early Estrogen Prevention Study (KEEPS)

A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women

Elacestrant in Advanced Triple Positive Breast Cancer

Estrogen and Perimenopausal Depression

Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Study Evaluating Premarin and Bazedoxifene Potential Interaction

Investigation of the Effect of the Female Urinary Microbiome on Incontinence

Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease

Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa

Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts